Drug reference
ciltacabtagene autoleucel
Cellular therapy (CAR-T)
Cellular therapy (CAR-T)
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
An anti-BCMA CAR transduced T cell therapy that targets and destroys myeloma cells expressing BCMA.
Indications
Relapsed multiple myeloma (after at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and refractory to lenalidomide)
Side effects
Serious
- Cytokine release syndrome
- Neurotoxicity
Related guidelines
Ask House about ciltacabtagene autoleucel
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team